Cefetecol is a broad-spectrum cephemcarboxylate derivative with antibacterial activity patented by British pharmaceutical company Glaxo Group Ltd.

Cefuroxime Pivoxetil is an ester prodrug of cefuroxime, a semisynthetic, broad-spectrum, beta-lactamase-resistant, second-generation cephalosporin with antibacterial activity. Cefuroxime binds to and inactivates penicillin-binding proteins (PBPs) located on the inner membrane of the bacterial cell wall. PBPs are enzymes involved in the terminal stages of assembling the bacterial cell wall and in reshaping the cell wall during growth and division. Inactivation of PBPs interferes with the cross-linkage of peptidoglycan chains necessary for bacterial cell wall strength and rigidity. This results in the weakening of the bacterial cell wall and causes cell lysis.

Sufotidine is a triazolamine derivative patented by Glaxo Group Ltd. as long-acting histamine H2-blocker useful for the treatment of peptic ulceration and oesophagitis. In phase II clinical treatment with sufotidine decreases median integrated 24-hour intragastric acidity by 95% compared with placebo. Twice daily sufotidine maintained the pH above 3 throughout the 24 h. Unfortunately, no further development report has been published and it seems, that Sufotidine development currently discontinued.

Cefetecol is a broad-spectrum cephemcarboxylate derivative with antibacterial activity patented by British pharmaceutical company Glaxo Group Ltd.